Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research
Free WhitepaperSchizophrenia: Using Digital Biomarkers to Measure Quality of Life The symptoms of schizophrenia spectrum illnesses are multifaceted and vary…
Cambridge Cognition
The spoken revolution in rater training assessment
Optimising outcome measures in cognitive drug trials for schizophrenia
The value of CNS-specific eCOA provider in clinical trials
Safety first: Cognition as a primary safety endpoint provides a competitive advantage
How to identify and remove CNS assessment errors to avoid jeopardising a trial
